<DOC>
	<DOCNO>NCT02441062</DOCNO>
	<brief_summary>Participants study diagnosed tumor carcinoid , neuroendocrine tumor , neuroblastoma , Ewing 's sarcoma , brain tumor cell carry somatostatin receptor . The purpose research study see tumor identify use special procedure call positron emission tomography ( PET ) scan result imaging procedure change management tumor .</brief_summary>
	<brief_title>Impact Ga-68 DOTATOC PET-CT Imaging Management Neuroendocrine Tumors</brief_title>
	<detailed_description>This prospective , Phase II , single center , open-label study total 200 participant histologically proven neuroendocrine tumor somatostatin receptor positive tumor . Eligible participant undergo baseline assessment enrollment . They receive 68Ga-DOTATOC undergo PET/CT imaging study . Participants may receive second 68Ga-DOTATOC PET/CT restaging therapy 12-36 month follow first scan .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Signed informed consent 2 . Age ≥ 6 month 3 . Histologically diagnosed neuroendocrine tumor tumor probable somatostatin receptor subtype 2 4 . Karnofsky performance status Lansky Play Scale status ≥ 60 ( ECOG/WHO equivalent ) 5 . Subject male ; female either surgically sterile ( documented bilateral oophorectomy and/or document hysterectomy ) , postmenopausal ( &gt; 1 year without menses ) , ≥60 year old , childbearing potential pregnancy test ( result know prior investigational product administration ) negative . A negative pregnancy test require female subject child bear potential . If false pregnancy test suspect , e.g. , perimenopausal condition , obstetrician consult determine is/is capable become pregnant . Female must also nonlactating . 1 . Subject weigh 450 pound . ( Subjects weigh 450 pound able fit inside image machine ) otherwise safely fit imaging system . 2 . Inability lie still entire imaging time ( due cough , severe arthritis , etc . ) 3 . Inability complete need investigational standardofcare image examination due reason ( severe claustrophobia , radiation phobia , etc . ) 4 . Any additional medical condition , serious intercurrent illness , extenuate circumstance , opinion investigator , may significantly interfere study compliance . 5 . Peptide receptor radionuclide therapy ( PRRT ) within 4 week Ga68 DOTATOC PET/CT scan . 6 . Treatment Sandostatin LAR within 4 week , SQ Octreotide within 12 hour , Lanreotide injection within 8 week Ga68 DOTATOC PET/CT ( +/5 % ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>